Introduction
============

Malignant melanoma (MM) is a highly aggressive cancer derived from neural crest melanocytes and occurs most frequently in the skin, digestive tract, eyes, genitals and nasal cavity ([@b1-ol-0-0-11219]--[@b3-ol-0-0-11219]) The prognosis of patients with MM is poor and the 5-year survival is reported to be \<20% ([@b4-ol-0-0-11219]). Each year, \~20,000 cases of cutaneous MM are reported in China and the incidence is growing by 3--5% per year ([@b5-ol-0-0-11219]). The incidence of MM is lower in China compared with Western countries, but survival is shorter in Chinese patients ([@b6-ol-0-0-11219],[@b7-ol-0-0-11219]). In addition, differences in incidence, etiology and clinical characteristics between different races are still poorly understood.

The development of prognostic markers of MM, such as serum lactic dehydrogenase (LDH) and the identification of new treatment targets; for example, melanogenesis, have improved the treatments available for patients and patient outcomes ([@b8-ol-0-0-11219],[@b9-ol-0-0-11219]). Serum LDH appears to be an independent marker of stage IV MM and studies have suggested that serum LDH may be used to identify patients requiring complete mastectomy ([@b1-ol-0-0-11219],[@b2-ol-0-0-11219]). However, to the best of our knowledge, it is unclear whether serum LDH can be used to predict the metastatic possibility in the early stages of MM.

In the present study, the prognostic value of commonly tested hematological and biochemical parameters were investigated, including serum albumin and prealbumin, LDH, total leukocyte count and serum D-dimer levels, a degradation product of fibrinolysis. In addition, the albumin/D-dimer ratio \[serum albumin/D-dimer prognosis score (ADPS)\] and the serum prealbumin/D-dimer ratio \[serum prealbumin/D-dimer prognosis score (PDPS)\] were determined. Serum albumin ([@b10-ol-0-0-11219]) and prealbumin levels ([@b11-ol-0-0-11219]) reflect the nutritional and inflammatory status of the patient. Malnourished patients with cancer often have poor immune function, drug tolerance and poor response to treatments ([@b12-ol-0-0-11219]). D-dimer has been found to be associated with malignancy and D-dimer levels are associated with tumor stage, tumor prognosis, lymph node involvement and survival of patients with several types of cancer, including esophageal squamous cell carcinoma ([@b13-ol-0-0-11219]), gastric cancer ([@b14-ol-0-0-11219]), breast cancer ([@b15-ol-0-0-11219]), colorectal cancer ([@b16-ol-0-0-11219]), lung cancer ([@b17-ol-0-0-11219]) and ovarian cancer ([@b18-ol-0-0-11219]). Moreover, cancer-associated inflammation is an important contributor to disease progression and survival, and systemic inflammation is associated with alterations in peripheral blood leukocytes ([@b19-ol-0-0-11219]). Therefore, in the present study, it was hypothesized that a combination of D-dimer levels, leukocyte count and albumin or prealbumin levels may be useful for predicting prognosis of patients with MM.

The aim of the present study was: i) To explore the characteristics of MM and the factors affecting prognosis in Chinese patients with MM; ii) analyze the similarities and differences in characteristics with patients with MM from other regions of the world; and iii) to determine the value of commonly tested hematological and biochemical parameters for predicting metastasis in patients with MM.

Patients and methods
====================

### Patients

The present study was approved by The Ethics Committee of the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China; trial registration no. 2018-LW-037). Written informed consent was obtained from all participants included in the study. A total of 176 patients at the First Affiliated Hospital of Zhengzhou University were collected. Patients with a history of other malignancies, autoimmune disease, chronic renal or hepatic disease, diabetes, thyroid disorders and taking anti-inflammatory drugs were excluded. A total of 167 patients were included in this study, including 74 men (44.3%) and 93 women (55.7%). All patients were diagnosed with cutaneous or mucosal MM according to the criteria of the American Joint Committee on Cancer, 8th edition ([@b1-ol-0-0-11219]) between April 2003 and April 2018. The age range of all patients was 22--92 years and the median age was 56.81 years. The demographic and clinical data of these patients was obtained from medical records for analysis; including personal data (age at diagnosis, sex, living habits, family history); blood test results (serum albumin and prealbumin, serum LDH, total leukocyte count, serum D-dimer); tumor-related data \[tumor location and stage, presence of metastasis, Breslow level ([@b20-ol-0-0-11219]), Clark level ([@b3-ol-0-0-11219]), presence of ulceration\]; treatment received (adjuvant therapy and type of surgery) and follow-up data (current status, survival). [Table I](#tI-ol-0-0-11219){ref-type="table"} summarizes the collected data.

### cBioPortal

The characteristics of the patients of the present study were compared with patients around the world registered in the cBioPortal for Cancer Genomics ([cbioportal.org](cbioportal.org)). cBioPortal combines a number of large-scale cancer genomics projects, including The Cancer Genome Atlas (<https://www.cancer.gov/tcga>) and The International Cancer Genome Consortium (<https://icgc.org/>), and catalogues data on genetic, epigenetic, gene expression and proteomic events. The portal also provides graphical summaries of gene-level data from multiple platforms, network visualization and analyses, survival analysis ([@b21-ol-0-0-11219]) patient-centric queries and software programmatic access ([@b2-ol-0-0-11219]). cBioPortal contained 12 studies with a total of 1,566 patients, focusing on melanoma of eye and skin ([Table II](#tII-ol-0-0-11219){ref-type="table"}). Following elimination of duplicate data, a total of 1,518 patients remained, including 97% of Caucasian patients from America and Europe and 3% of Asian or African patients ([Fig. 1A](#f1-ol-0-0-11219){ref-type="fig"}).

### Statistical analysis

Data were analyzed using Microsoft Excel 2007 (Microsoft Corporation), SPSS version 20.0 (IBM Corp.) and GraphPad Prism version 5 (GraphPad Software Inc.). Quantitative variables were presented as either mean ± standard deviation or median and interquartile range, depending on the normality of the distribution. Normally distributed quantitative variables were analyzed using a Student\'s t test, data with unequal variance were analyzed using a Welch\'s t-test. Non-normally distributed continuous data were compared using a Mann-Whitney U test. Qualitative variables were reported as frequencies and percentages and compared using a χ^2^ test or the Fisher\'s exact test. Receiver operating characteristic (ROC) analysis was used to identify the ideal cutoff value of ADPS for distinguishing between patients with and without metastasis. The Youden index \[(specificity + sensitivity)-1\] was calculated as a measure of overall efficacy. The area under curve (AUC) was used to assess the predictive value of ADPS, serum prealbumin/D-dimer prognosis score (PDPS) and D-dimer. Regression tree analysis was used to measure the sensitivity, specificity and accuracy of the indicator for predicting metastasis in patients with MM. Variables that were significantly associated with tumor metastasis were analyzed using multivariate Cox regression analysis to identify independent predictors of metastasis. Kaplan-Meier curves were constructed for survival analysis and a log-rank test was used to determine the differences in survival rate. In Kaplan-Meier survival analysis of prognostic factors for OS, the prognostic factors with multigroups in T stage, TNM stage, Breslow thickness, Clark level, histological type and anatomic region were analyzed by pooled over strata in log-rank test. P\<0.05 was considered to indicate a statistically significant difference. In the comparison of MM patients with and without metastasis, each numerical data was limited by the mean difference and divided into higher group and lower group. Regarding other statistic analyses, MM patients were divided into low or high group according to the ADPS value (341.01), the ideal cutoff value by ROC analysis, whereas other quantitative data were grouped by mean value.

Results
=======

### Clinical characteristics of patients with MM

A total of 85 patients (50.9%) were still alive at the end of the study whereas 82 patients (49.1%) had died. Median overall survival (OS) was 50 months (range, 0--181 months; [Fig. 1C](#f1-ol-0-0-11219){ref-type="fig"}) and median disease-free survival (DFS) was 35 months (range, 0--124 months; [Fig. 1D](#f1-ol-0-0-11219){ref-type="fig"}). The proportion of patients with tumor node metastasis (TNM) stage I/II, III or IV were 64/167 (38.3%), 38/167 (22.8%) and 65/167 (38.9%), respectively. Data on Breslow thickness were available for 137 patients; the Breslow thickness was \<1 mm in 42/137 patients (30.7%), 1.01--2.00 mm in 48/137 patients (35.0%), 2.01--4.00 mm in 27/137 patients (19.7%) and \>4.00 mm in 20/137 patients (14.6%). Data on the Clark level were available for 138 patients; 30/138 patients (21.7) were classed as level 1, 34/138 patients (21.7%) were classed as level 2, 41/138 patients (29.7%) were classed as level 3, 16/138 patients (11.6%) were classed as level 4 and 17/138 patients (12.3%) were classed as level 5. The primary lesion was on the trunk in 21/167 patients (12.6%), in the head/neck region in 14/167 patients (8.4%), in the extremities in 97/167 patients (58.1%), in the mucosa in 24/167 patients (37.8%) and at unknown locations in 11/167 patients (6.6%). Ulcerative melanoma was observed in 88 out of 167 patients (52.7%) and nonulcerative melanoma was observed in 59 out of 167 patients (35.3%). The mean total serum Albumin, D-dimer and LDH were 42.83±3.32 g/l, 0.208±0.209 ug/l and 183.78±55.54 U/l, respectively. The clinicopathological characteristics of patients and results of blood tests are described in [Table I](#tI-ol-0-0-11219){ref-type="table"}.

### Comparison of characteristics of Chinese patients with MM with the cBioPortal data

The proportion of male patients was higher in the cBioPortal cohort than in the experimental cohort (61% vs. 44%; [Fig. 1Fa and Fb](#f1-ol-0-0-11219){ref-type="fig"}). Age at diagnosis of patients with MM ranged from 40--70 years in both the cBioPortal cohort and in experimental cohort ([Fig. 1Ba and Bb](#f1-ol-0-0-11219){ref-type="fig"}). MM was most commonly diagnosed in patients aged 50--60 years in the cBioPortal cohort ([Fig. 1Ba](#f1-ol-0-0-11219){ref-type="fig"}); whereas, in the experimental cohort MM was most commonly diagnosed in patients aged 60--70 years ([Fig. 1Bb](#f1-ol-0-0-11219){ref-type="fig"}). Median OS was 66.43 months (range, 0.36--369.65 months) in the cBioPortal cohort vs. 50 months (range, 0--181 months) in the experimental cohort. Median DFS was 49.21 months (range, 0.46--386.50 months) in the cBioPortal cohort vs. 35 months (range, 0--112 months) in experimental cohort. The 3-, 5- and 10-year survival rates were 59.1, 47.7 and 31.6%, respectively, in the cBioPortal cohort vs. 59.0, 43.0 and 13.5% in the experimental cohort ([Fig. 1C and D](#f1-ol-0-0-11219){ref-type="fig"}). OS was 47% in the cBioPortal cohort vs. 49% in experimental cohort ([Fig. 1E](#f1-ol-0-0-11219){ref-type="fig"}). In the cBioPortal cohort, the most common locations of melanoma were the trunk (54%), followed by the extremities (22%), head and neck (16%) and mucosa (5%) ([Fig. 1Ga](#f1-ol-0-0-11219){ref-type="fig"}), whereas in the experimental cohort the most common locations of melanoma were the extremities (58.1%), followed by the mucosa (14%) and the trunk (13%) ([Fig. 1Gb](#f1-ol-0-0-11219){ref-type="fig"}). The reasons for these differences remain unclear; however, a possible explanation may be due to differences in lifestyle factors.

### Melanoma treatment

Patients in the experimental cohort received a variety of treatments, including combinations of surgery, chemotherapy, immunotherapy and biotherapy. A total of 88/167 patients (52.7%) received surgery and adjuvant therapy, whereas 59/167 patients (35.3%) received only surgery and 14/167 patients (8.4%) received only adjuvant therapy ([Fig. 2](#f2-ol-0-0-11219){ref-type="fig"}); treatment details were not available for 6/167 (3.6%) patients ([Table I](#tI-ol-0-0-11219){ref-type="table"}). Treatment selection for the patients in the experimental cohort was in accordance with the 1st edition of Consensus on the Diagnosis and Treatment of Melanoma in China (August, 2008) ([@b1-ol-0-0-11219]). Chemotherapeutic agents used included Taxol, Dacarbazine and platinum-type drugs. Immunotherapeutic agents used included thymopentin, and recombinant human interferon g and/or interleukin-2. There were a total of 15 different combinations of treatments; the most common treatment was surgery alone, followed by surgery plus immunotherapy and then surgery plus bioimmunotherapy ([Fig. 2](#f2-ol-0-0-11219){ref-type="fig"}).

### Comparison of patients with and without metastasis

The experimental patients were separated into two groups: Patients with metastasis (n=104) and those without metastasis (n=63). Mean serum albumin (P=0.145), prealbumin (P=0.752), LDH (P=0.150) and leukocyte count (P=0.224) did not significantly differ between the two groups. However, patients with metastasis had significantly higher D-dimer levels (0.237±0.217 µg/l vs. 0.151±0.134 µg/l; P\<0.001), and a significantly lower ADPS (328.61±235.72 vs. 452.46±302.07; P\<0.001) and PDPS (1,913.53±1,464.42 vs. 2,657.75±1,983.42; P\<0.05) ([Table III](#tIII-ol-0-0-11219){ref-type="table"}).

### ROC analysis

ROC analysis showed an ADPS of 341.01 to be the ideal cutoff value for differentiating between patients with and without metastasis and the AUC for ADPS was 0.773 ([Fig. 3](#f3-ol-0-0-11219){ref-type="fig"}). For prediction of metastasis, ADPS had 93.8% sensitivity, 59.6% specificity, 54.6% accuracy and a Youden index of 53.40%. The AUC for PDPS was 0.547. For prediction of metastasis, PDPS had 31.3% sensitivity, 84.7% specificity, 9.4% accuracy and a Youden index of 16.0%. The AUC for D-dimer was 0.447. For prediction of metastasis, D-dimer had 31.35% sensitivity, 75.5% specificity, 10.6% accuracy and a Youden index of 6.9% ([Table IV](#tIV-ol-0-0-11219){ref-type="table"}).

### Univariate and multivariable Cox regression analyses for metastasis of patients with MM

Univariate Cox regression analyses were performed to screen the potential predictors of metastasis for patients with MM. A total of 9 clinicopathological predictors for overall survival were ascertained through multivariate Cox regression analysis and 3 variables were shown to be independently associated with metastasis; including ADPS Group \[hazard ratio (HR)=8.534; 95% confidence interval (CI)= 3.109--23.425\], ulceration (HR=4.287; 95% CI=2.204--8.953) and vertical growth phase (HR=2.324; 95% CI=1.067--5.063). In contrast, sex, Breslow thickness, Clark level, histological type, anatomic location and T stage were not shown to be independent predictors of metastasis ([Tables V](#tV-ol-0-0-11219){ref-type="table"} and [VI](#tVI-ol-0-0-11219){ref-type="table"}).

### Kaplan-Meier survival analysis of prognostic factors for OS

A 10-year Kaplan-Meier survival analysis was performed and a Log-rank test was used to compare the survival curves of two or more groups. Survival of patients with high ADPS was significantly longer compared with patients with low ADPS. The OS was significantly worse for MM patients with ulcerated melanoma (compared with patients without ulceration; P\<0.001; [Fig. 4I](#f4-ol-0-0-11219){ref-type="fig"}), MM patients with metastasis (compared with patients without metastasis; P\<0.001; [Fig. 4J](#f4-ol-0-0-11219){ref-type="fig"}), female patients (compared with male patients; P=0.0062; [Fig. 4A](#f4-ol-0-0-11219){ref-type="fig"}), Clark level \>3 (compared with Clark level 3 and 4; P\<0.001; [Fig. 4E](#f4-ol-0-0-11219){ref-type="fig"}) and patients with vertical growth phase (compared with radial; P\<0.001; [Fig. 4G](#f4-ol-0-0-11219){ref-type="fig"}). The Kaplan-Meier survival curves also demonstrated significant difference in distinct TNM stage (multiple comparison; P\<0.001; [Fig. 4C](#f4-ol-0-0-11219){ref-type="fig"}) and Breslow thickness (multiple comparison; P\<0.001; [Fig. 4D](#f4-ol-0-0-11219){ref-type="fig"}). The median OS by stage was as follows: T0 stage, 8 months; T1 stage, 108 months; T2 stage, 60 months; T3 stage, 27 months; and T4 stage, 19 months (multiple comparison; P\<0.001; [Fig. 4B](#f4-ol-0-0-11219){ref-type="fig"}). Median overall survival by histological type was as follows: Acral lentiginous melanoma, 82 months; nodular melanoma, 21 months; superficial spreading melanoma, 74 months; Lentigo malignant melanoma, 50 months; Mucosal melanoma, 47 months; and indeterminate types, 6 months (multiple comparison; P\<0.001; [Fig. 4H](#f4-ol-0-0-11219){ref-type="fig"}). Anatomic region of the MM was not associated with OS (multiple comparison; P=0.171; [Fig. 4F](#f4-ol-0-0-11219){ref-type="fig"}; [Table VII](#tVII-ol-0-0-11219){ref-type="table"}).

### Comparison between patients with low and high ADPS

ADPS was calculated for 124 patients. There were 24 patients with low ADPS (\<341.01) and 99 patients with high ADPS (≥341.01). Patients with high ADPS level were more likely to have a longer OS (P=0.016), DFS (P=0.001) and earlier TNM stage (TNM stages I and II) of MM (24.2% vs. 17.4%; P=0.008), whereas these patients were less likely to have an ulcerated melanoma (19.9% vs. 20.6%; P\<0.001) or a metastatic melanoma (17.4% vs. 24.2%; P=0.002; [Table VIII](#tVIII-ol-0-0-11219){ref-type="table"}).

Discussion
==========

Due to the low incidence of MM in China there is still no standard approach for diagnosis and treatment, and this is partly due to a lack of reliable indicators of metastasis in the early stages of disease. The aim of the present study was to determine the prognostic value of specific hematological and biochemical parameters routinely assessed at admission to hospital, and their predictive value for prognosis of patients with MM.

Prognostic markers of MM, such as serum LDH, and the identification of new treatment targets including melanogenesis, serve important roles in the treatment and prognosis of MM ([@b9-ol-0-0-11219]). Melanogenesis is a highly regulated multistep biochemical process of melanin production by melanocytes ([@b22-ol-0-0-11219],[@b23-ol-0-0-11219]). Previous studies have indicated that melanin pigment increases the resistance of melanoma cells to different types of therapy including chemo- or radiotherapy ([@b22-ol-0-0-11219]). Regarding the role of melanin pigment in chemoresistance of melanoma cells, it was reported that melanogenesis can generate cytotoxic, genotoxic or mutagenic intermediates, which influence tumor microenvironment and tumor immunity ([@b24-ol-0-0-11219]). Furthermore, studies have shown that melanogenesis reduces OS and DFS in patients with MM ([@b23-ol-0-0-11219]).

Serum albumin is synthesized in the liver and participates in numerous biological functions in the body, including maintenance of plasma osmotic pressure and regulation of the dynamic balance between tissue fluid and blood vessels ([@b25-ol-0-0-11219],[@b26-ol-0-0-11219]). Serum albumin is also essential for the transport of a number of substances, including hormones, long-chain fatty acids to the liver, unconjugated bilirubin, metals and ions ([@b27-ol-0-0-11219],[@b10-ol-0-0-11219]). Decreases in plasma albumin levels can result in decreased activity of enzymes essential for metabolism of organisms ([@b28-ol-0-0-11219]). Serum albumin levels can be used to assess nutritional and inflammatory status ([@b28-ol-0-0-11219]). It has also been demonstrated that malnourished cancer patients often have reduced immune function, poor drug tolerance and poor response to treatments ([@b12-ol-0-0-11219],[@b29-ol-0-0-11219]).

D-dimer is a by-product of fibrinolysis and increases in the levels of D-dimers suggest the presence of coagulation and fibrinolysis ([@b30-ol-0-0-11219]). Plasma D-dimer levels are useful for monitoring the state of thrombotic diseases and disseminated intravascular coagulation ([@b13-ol-0-0-11219]). Several studies have shown that the levels of D-dimer are associated with tumor stage, tumor prognosis, lymph node involvement and survival of patients with ovarian cancer ([@b18-ol-0-0-11219]). In addition, increased D-dimer levels are associated with the degree of malignancy of tumors. Tumor cells or necrotic tissues stimulate the generation and release of coagulation-promoting substances, which activate exogenous coagulation factors resulting in abnormal coagulation and thus activation of the plasminogen activator ([@b30-ol-0-0-11219],[@b31-ol-0-0-11219]). Locally synthesized fibrinolytic enzymes degrade the extracellular matrix and facilitate tumor invasion ([@b14-ol-0-0-11219]).

In the present study, significant differences in D-dimer levels, ADPS and PDPS were observed in patients with metastasis compared with those without metastasis ([Table III](#tIII-ol-0-0-11219){ref-type="table"}). ROC analysis and multivariate Cox regression analysis showed that ADPS was an independent predictor of metastasis for patients with MM. Previous studies reported that albumin and D-dimer served as independent prognostic predictors of prognosis of patients with miliary tuberculosis ([@b32-ol-0-0-11219]) and the postoperative survival of patients with esophageal squamous cell carcinoma ([@b13-ol-0-0-11219]). In other studies investigating MM, low serum albumin levels are predictors of morbidity and mortality in patients with MM ([@b33-ol-0-0-11219]) and elevated D-dimer levels indicated a poor prognosis ([@b32-ol-0-0-11219]). However, to the best of our knowledge, the present study is the first to show ADPS as an independent predictor of MM metastasis.

In the present study, the highest incidence of MM was observed in individuals aged between 40--70 years, similar to the reports from other studies with Chinese cohorts ([@b32-ol-0-0-11219]). Statistical analysis showed ulceration and vertical growth phase were independent risk factors for tumor metastasis in patients with MM and previous studies have also identified ulceration as an independent prognostic factor in patients with melanoma ([@b34-ol-0-0-11219]). In certain Chinese studies \>4 mm tumor thickness and clinical stage III and IV were also found to be significant predictive factors ([@b5-ol-0-0-11219]).

In the experimental cohort used in the present study, surgery was the most common treatment, followed by surgery combined with immunotherapy, and surgery combined with bioimmunotherapy. To the best of our knowledge, it is unclear if surgery is the best choice to completely remove all lesions in patients with MM with locally advanced or early disease and in patients with distant MM metastasis. However, previous studies have shown that patients with MM with distant metastasis may still benefit from surgery ([@b35-ol-0-0-11219],[@b36-ol-0-0-11219]). Patients with stage IV MM are usually treated with systemic biologics and/or chemotherapy; however, treatment for patients with metastatic MM has been a challenge as aggressive treatments, including combination of immunotherapy with other therapies, have failed to show satisfactory efficacy ([@b37-ol-0-0-11219],[@b38-ol-0-0-11219]).

The cohort of the present study was compared with the cohort of patients with MM in cBioPortal and significant differences were found, including differences in OS, DFS, age at diagnosis and anatomic locations of metastasis between the two groups of patients. There may be several reasons for these differences, for example the sample size of the experimental cohort in the present study was small, and Caucasians comprised a majority of the patients in the cBioPortal cohort, whereas all the patients in the present study were Chinese. Melanoma is more common in light-skinned individuals, as individuals lacking protective melanin pigments are more susceptible to cutaneous melanoma compared with darker-skinned individuals ([@b22-ol-0-0-11219]). Therefore lower quantities of protective melanin pigment may increase the susceptibility of Caucasians to damage caused by ultraviolet radiation ([@b22-ol-0-0-11219],[@b24-ol-0-0-11219]). Previous epidemiological and experimental data have indicated that ultraviolet light, through its mutagenic activity, is the most likely cause of cutaneous melanoma in Caucasian patients ([@b39-ol-0-0-11219]). MM in Caucasian patients also predominantly occurs on the trunk and the most common type is the superficial spreading type ([@b40-ol-0-0-11219]); however, in Chinese patients, MM occurs most frequently on the extremities or the mucosa ([@b41-ol-0-0-11219]). Moreover, the majority of Caucasian patients are diagnosed at stage I ([@b20-ol-0-0-11219]), whereas the majority of Chinese patients are diagnosed at stage II or III ([@b41-ol-0-0-11219]). The reasons for these ethnic differences should be a focus of future studies.

The present study has certain limitations. First, the sample size was small, and all patients were recruited from a single institution. However, the First Affiliated Hospital of Zhengzhou University is a major referral center for MM treatment in central China, and the study population can be considered representative of this region. Second, some patients were lost to follow-up as a number of patients failed to comply with regular follow-up due to economic reasons or lack of awareness.

Overall, there are significant differences between patients with MM from central China and those from other parts of the world. ADPS may be a useful predictor of MM metastasis in the early stages of disease.
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:   serum albumin/D-dimer prognosis score
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###### 

Clinicopathological characteristics of patients with MM from the experimental cohort.

  Variable                             n     Mean ± standard deviation/proportion, %
  ------------------------------------ ----- -----------------------------------------
  OS, months                           167   35.9±31.6
  DFS, months                          167   26.9±28.8
  Age, years                           167   56.8±15.0
    ≤40                                23    13.8%
    40--50                             39    22.7%
    50--60                             33    20.4%
    60--70                             44    26.3%
    70--80                             20    12.0%
    \>80                               8     4.8%
  Sex                                  167   
    Male                               74    44.3%
    Female                             93    55.7%
  Overall survival status              167   
    Alive                              85    50.9%
    Deceased                           82    49.1%
  Family history of tumor              167   
    Yes                                24    14.4%
    No                                 97    58.1%
    Unknown                            46    27.5%
  T stage                              167   
    pT0                                13    7.9%
    pT1                                42    25.1%
    pT2                                57    34.1%
    pT3                                36    21.5%
    pT4                                19    11.4%
  TNM stage                            167   
    I or II                            64    38.3%
    III                                38    22.8%
    IV                                 65    38.9%
  Breslow, mm                          137   
    ≤1.00                              42    30.7%
    1.01--2.00                         48    35.0%
    2.01--4.00                         27    19.7%
    \>4.00                             20    14.6%
  Clark                                138   
    1                                  30    21.7%
    2                                  34    24.6%
    3                                  41    29.7%
    4                                  16    11.6%
    5                                  17    12.3%
  Histological type                    167   
    ALM                                52    13.8%
    NM                                 24    22.7%
    SSM                                33    20.4%
    LMM                                22    26.3%
    MCM                                24    12.0%
    Unclassifiable                     12    4.8%
  Growth phase                         130   
    Radial                             61    46.9%
    Vertical                           69    53.0%
  Anatomic region                      167   
    Trunk                              21    12.6%
    Head/neck                          14    8.4%
    Extremities                        97    58.1%
    Mucosal                            24    14.4%
    Unknown                            11    6.6%
  Ulceration                           147   
    With                               88    52.7%
    Without                            59    35.3%
    Unknown                            20    13.0%
  Metastasis                                 
    With                               104   62.3%
    Without                            63    37.7%
  Therapy                              167   
    Surgery                            59    35.3%
    Adjuvant therapy without surgery   14    8.4%
    Adjuvant therapy with surgery      88    52.7%
    Without therapy                    6     3.6%
  Albumin, g/l                         109   42.83±3.32
  Prealbumin, mg/l                     100   244.60±54.26
  D-dimer, ug/l                        105   0.208±0.209
  Leukocyte 10^9^/l                    113   6.56±2.17
  LDH, U/l                             96    183.78±55.54

T0, no evidence of primary tumor; OS, overall survival; DFS, disease free survival; T, tumor; TNM, tumor node metastasis; ALM, acral lentiginous melanoma; MCM, mucosal melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; LDH, lactate dehydrogenase.

###### 

Results of tumor type and number of cases from cBioPortal.

  Author, year                                                                                                                           Source                                                                              Cancer type                                                                     No. of cases   (Refs.)
  -------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------- --------------------------------------------
  Taylor *et al*, 2018; Sanchez-Vega *et al*, 2018; Liu *et al*, 2018; Hoadley *et al*, 2018; Gao *et al*, 2018; Ellrott *et al*, 2018   TCGA, PanCancer Atlas                                                               Uveal melanoma                                                                  80             ([@b42-ol-0-0-11219]--[@b47-ol-0-0-11219])
  2018                                                                                                                                   TCGA, provisional^[a](#tfn2-ol-0-0-11219){ref-type="table-fn"}^                     Uveal melanoma                                                                  80             
  Liang *et al*, 2017                                                                                                                    TGEN, genome research, 2017                                                         Paired-exome sequencing of acral melanoma                                       38             ([@b48-ol-0-0-11219])
  Berger *et al*, 2012                                                                                                                   Broad/Dana Farber, nature 2012                                                      Cutaneous melanoma                                                              26             ([@b49-ol-0-0-11219])
  2017                                                                                                                                   MSKCC, JCO precision oncology, 2017^[b](#tfn3-ol-0-0-11219){ref-type="table-fn"}^   Next generation sequencing (NGS) of pre-treatment metastatic melanoma samples   66             
  Hodis *et al*, 2012                                                                                                                    Broad, cell, 2012                                                                   Skin cutaneous melanoma                                                         121            ([@b50-ol-0-0-11219])
  Taylor *et al*, 2018; Sanchez-Vega *et al*, 2018; Liu *et al*, 2018; Hoadley *et al*, 2018; Gao *et al*, 2018; Ellrott *et al*, 2018   TCGA, PanCancer Alas                                                                Skin cutaneous melanoma                                                         448            ([@b42-ol-0-0-11219]--[@b47-ol-0-0-11219])
  2018                                                                                                                                   TCGA, provisional                                                                   Skin cutaneous melanoma^[a](#tfn2-ol-0-0-11219){ref-type="table-fn"}^           479            
  Krauthammer *et al*, 2012                                                                                                              Yale, nat genet 2012                                                                Skin cutaneous melanoma                                                         91             ([@b51-ol-0-0-11219])
  Van Allen *et al*, 2014                                                                                                                Broad, cancer discov 2014                                                           Skin cutaneous melanoma                                                         78             ([@b52-ol-0-0-11219])
  Hugo *et al*, 2016                                                                                                                     UCLA, cell 2016                                                                     Whole-exome sequences of pretreatment melanoma tumors                           39             ([@b53-ol-0-0-11219])
  Shain *et al*, 2015                                                                                                                    Broad institute, nat genet 2015                                                     Desmoplastic melanoma                                                           20             ([@b54-ol-0-0-11219])

Raw data at the National Cancer Institute (<https://www.cancer.gov/tcga>).

Next generation sequencing (NGS) of pre-treatment. TCGA, The Cancer Genome Atlas; MSKCC, Memorial Sloan-Kettering Cancer Center; UCLA, University of California, Los Angeles.

###### 

Comparison between experimental cohort patients with and without metastatic MM.

  Variable                                                           Metastatic, mean ± SD   Non-metastatic^[h](#tfn11-ol-0-0-11219){ref-type="table-fn"}^, mean ± SD or mean (n=%)   P-value
  ------------------------------------------------------------------ ----------------------- ---------------------------------------------------------------------------------------- -------------------------------------------------------
  Albumin, g/l^[d](#tfn7-ol-0-0-11219){ref-type="table-fn"}^         42.12±4.35              42.99±2.90                                                                               0.145
  Prealbumin, mg/l^[e](#tfn8-ol-0-0-11219){ref-type="table-fn"}^     246.90±57.58            243.70±50.70                                                                             0.752
  LDH, U/l^[f](#tfn9-ol-0-0-11219){ref-type="table-fn"}^             191.43±59.86            176.56±37.22                                                                             0.150
  D-dimer, ug/l^[f](#tfn9-ol-0-0-11219){ref-type="table-fn"}^        0.43±0.85               0.16±0.13                                                                                \<0.001
  Leukocyte, 10^9^/l^[f](#tfn9-ol-0-0-11219){ref-type="table-fn"}^   6.77±4.58               5.93±1.97                                                                                0.224
  ADPS^[f](#tfn9-ol-0-0-11219){ref-type="table-fn"}^                 290.46±241.84           434.35±276.99                                                                            \<0.001
  PDPS^[e](#tfn8-ol-0-0-11219){ref-type="table-fn"}^                 1,789.50±1,449.42       2,521.04±1,809.78                                                                        0.018^[a](#tfn4-ol-0-0-11219){ref-type="table-fn"}^
  Sex                                                                                                                                                                                 \<0.001^[c](#tfn6-ol-0-0-11219){ref-type="table-fn"}^
    Male                                                             57 (54.8%)              17 (25.8%)                                                                               
    Female                                                           47 (45.2%)              49 (74.2%)                                                                               
  Breslow^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                              \<0.001^[c](#tfn6-ol-0-0-11219){ref-type="table-fn"}^
    ≤1.00                                                            12 (16.0%)              29 (50.0%)                                                                               
    1.01--2.00                                                       28 (37.3%)              19 (32.8%)                                                                               
    2.01--4.00                                                       18 (24.0%)              8 (13.8%)                                                                                
    \>4.00                                                           17 (22.7%)              2 (3.4%)                                                                                 
  Clark level^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                          \<0.010^[a](#tfn4-ol-0-0-11219){ref-type="table-fn"}^
    1                                                                12 (16.0%)              17 (29.8%)                                                                               
    2                                                                14 (18.7%)              19 (33.3%)                                                                               
    3                                                                25 (33.3%)              15 (26.3%)                                                                               
    4                                                                11 (14.7%)              4 (7.0%)                                                                                 
    5                                                                13 (17.3%)              2 (3.5%)                                                                                 
  Anatomic region^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                      0.078
    Truck                                                            16 (17.0%)              5 (7.9%)                                                                                 
    Head/neck                                                        10 (10.6%)              4 (6.3%)                                                                                 
    Extremities                                                      51 (54.3%)              47 (74.6%)                                                                               
    Mucosal                                                          7 (18.1%)               7 (11.1%)                                                                                
  Ulceration^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                           \<0.001^[c](#tfn6-ol-0-0-11219){ref-type="table-fn"}^
    With                                                             69 (80.2%)              19 (31.1%)                                                                               
    Without                                                          17 (19.8%)              42 (68.9%)                                                                               
  T stage^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                              0.003^[b](#tfn5-ol-0-0-11219){ref-type="table-fn"}^
    pT0                                                              13 (7.8%)               0 (0)                                                                                    
    pT1                                                              11 (6.6%)               31 (18.6%)                                                                               
    pT2                                                              38 (22.8%)              19 (11.4%)                                                                               
    pT3                                                              25 (15.0%)              11 (6.6%)                                                                                
    pT4                                                              17 (10.2%)              2 (1.2%)                                                                                 
  Histological type^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                    \<0.001^[c](#tfn6-ol-0-0-11219){ref-type="table-fn"}^
    ALM                                                              21 (13.5%)              31 (20.0%)                                                                               
    NM                                                               23 (14.8%)              1 (0.6%)                                                                                 
    SSM                                                              17 (11.0%)              16 (10.3%)                                                                               
    LMM                                                              14 (9.0%)               8 (5.1%)                                                                                 
    MCM                                                              17 (11.0%)              7 (4.5%)                                                                                 
  Growth phase^[g](#tfn10-ol-0-0-11219){ref-type="table-fn"}^                                                                                                                         \<0.001^[c](#tfn6-ol-0-0-11219){ref-type="table-fn"}^
    Radial                                                           15 (20.3%)              46 (82.1%)                                                                               
    Vertical                                                         59 (79.7%)              10 (17.9%)                                                                               

P\<0.05

P\<0.01

P\<0.001.

Mean ± SD, P-value based on Welch\'s t-test

Mean ± SD, P-value based on Student\'s t-test

Mean ± SD, P-value based on Mann-Whitney U test

P-value based on χ^2^ test

Unresectable melanoma. SD, standard deviation; MM, malignant melanoma; LDH, lactate dehydrogenase; ADPS, serum albumin/D-dimer prognosis score; PDPS, serum prealbumin/D-dimer prognosis score; T, tumor; ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; MCM, mucosal melanoma.

###### 

ROC analysis of metastasis in patients with MM.

            AUC     SE^[a](#tfn12-ol-0-0-11219){ref-type="table-fn"}^   Cut off value   Acurrency ratio, %   Sensitivity, %   Specificity, %   LB      UB      Youden index (%)
  --------- ------- --------------------------------------------------- --------------- -------------------- ---------------- ---------------- ------- ------- ------------------
  ADPS      0.773   0.045                                               457.38          54.60                93.8             59.6             0.686   0.861   53.40
  PDPS      0.547   0.082                                               3,456.61        9.40                 31.30            84.70            0.386   0.707   16.00
  D-dimer   0.447   0.084                                               0.238           10.60                31.35            75.50            0.282   0.611     6.85

Non-parametric. MM, malignant melanoma; SE, standard error; AUC, area under the curve; ROC, receiver operating characteristic; LB, 95% confidence interval lower bound; UB, 95% confidence interval upper bound.

###### 

Univariate Cox regression analyses of metastasis in patients with MM.

                      Univariate analysis                   
  ------------------- --------------------- --------------- -------
  ADPS group          13.611                6.707--27.622   0.000
  Ulceration          5.257                 3.036--9.102    0.000
  Growth phase        5.475                 3.074--9.752    0.000
  Sex                 −0.580                0.339--0.737    0.000
  Breslow             1.749                 1.415--2.162    0.000
  Clark level         1.507                 1.261--1.801    0.000
  T stage             1.423                 1.272--1.592    0.000
  Histological type                                         
    ALM               −0.114                0.054--0.242    0.000
    NM                −0.556                0.273--1.131    0.105
    SSM               −0.167                0.077--0.361    0.000
    LMM               −0.207                0.093--0.462    0.000
    MCM               −0.226                0.104--0.492    0.000
  Anatomic region                                           
    Trunk             −0.311                0.142--0.682    0.004
    Head/neck         −0.303                0.126--0.729    0.008
    Extremities       −0.189                0.096--0.375    0.000
    Mucosal           −0.259                0.118--0.568    0.001

ADPS, serum albumin/D-dimer prognosis score; T, tumor; ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; MCM, mucosal melanoma.

###### 

Multivariate Cox regression analyses of metastasis in patients with MM.

                      Multivariate analysis                           
  ------------------- ----------------------- ------- --------------- -------
  ADPS group          2.144                   8.534   3.109--23.425   0.000
  Ulceration          1.567                   4.792   2.204--8.953    0.000
  Growth phase        0.843                   2.324   1.067--5.063    0.034
  Sex                 −0.535                  0.586   0.314--1.092    0.092
  Breslow             0.339                   1.404   0.739--2.666    0.300
  Clark level         0.047                   1.048   0.820--1.339    0.708
  T stage             0.498                   1.645   0.857--3.158    0.134
  Histological type   −0.109                  0.896   0.653--1.230    0.498
  Anatomic region     0.035                   1.035   0.718--1.493    0.853

MM, malignant melanoma; HR, hazard ratio; CI, confidence interval; ADPS, serum albumin/D-dimer prognosis score; T, tumor; ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; MCM, mucosal melanoma.

###### 

Kaplan-Meier survival analysis of prognostic factors for OS.

  Variables            Median OS, months   df   Log-rank analysis, P value
  -------------------- ------------------- ---- --------------------------------------------------------
  Sex                                      1    0.0062^[b](#tfn16-ol-0-0-11219){ref-type="table-fn"}^
    Male               32                       
    Female             64                       
  T stage                                  4    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    pT0                8                        
    pT1                108                      
    pT2                60                       
    pT3                27                       
    pT4                19                       
  TNM stage                                2    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    I or II            120                      
    III                60                       
    IV                 14                       
  Breslow, mm, n=137                       3    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    ≤1.00              98                       
    1.01--2.00         60                       
    2.01--4.00         27                       
    \>4.00             24                       
  Clack level, n=138                       4    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    1                  83                       
    2                  60                       
    3                  37                       
    4                  40                       
    5                  24                       
  Histological type                        5    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    ALM                82                       
    NM                 21                       
    SSM                74                       
    LMM                50                       
    MCM                47                       
    Unclassifiable     6                        
  Growth phase                             1    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    Radial             98                       
    Vertical           32                       
  Anatomic region                          3    0.171
    Trunk              48                       
    Head/neck          69                       
    Extremities        89                       
    Mucosal            45                       
  Ulceration, n=147                        1    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    With               79                       
    Without            27                       
  Metastasis                               1    \<0.001^[c](#tfn17-ol-0-0-11219){ref-type="table-fn"}^
    With               24                       
    Without            113                      
  ADPS group                                    0.0035^[b](#tfn16-ol-0-0-11219){ref-type="table-fn"}^
    Low                24                  1    
    High               99                       
  LDH group                                1    0.010^[a](#tfn15-ol-0-0-11219){ref-type="table-fn"}^
    Low                89                       
    High               37                       

P\<0.05

P\<0.01

P\<0.001. n=167 unless otherwise specified. OS, overall survival; df, degree of freedom; T, tumor; TMN, tumor node metastasis; ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; MCM, mucosal melanoma; ADPS, serum albumin/D-dimer prognosis score; LDH, lactate dehydrogenase.

###### 

Comparison between patients with high ADPS level and low ADPS.

                                                                     Low ADPS level   High ADPS level   P-value
  ------------------------------------------------------------------ ---------------- ----------------- ------------------------------------------------------
  OS^[c](#tfn20-ol-0-0-11219){ref-type="table-fn"}^, mean ± SD       26.96±23.67      41.34±30.65       0.139
  DFS^[c](#tfn20-ol-0-0-11219){ref-type="table-fn"}^, mean ± SD      15.46±17.13      34.88±26.03       0.733
  TNM stage^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^, n (%)                                       1.000
  I or II                                                            25 (18.9%)       32 (24.2%)        
  III                                                                20 (15.2%)       12 (9.1%)         
  IV                                                                 32 (24.2%)       11 (8.3%)         
  Sex^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^, n (%)                                             0.644
  Male                                                               30 (25.6%)       21 (17.9%)        
  Female                                                             36 (56.4%)       30 (25.6%)        
  Breslow^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                                0.335
  ≤1.00                                                              20 (17.1%)       17 (14.5%)        
  1.01--2.00                                                         19 (16.2%)       21 (17.9%)        
  2.01--4.00                                                         16 (13.7%)       8 (6.8%)          
  \>4.00                                                             11 (9.4%)        5 (4.3%)          
  Clark level^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                            0.713
  1                                                                  18 (14.9%)       9 (7.4%)          
  2                                                                  15 (12.4%)       15 (12.4%)        
  3                                                                  17 (14.0%)       16 (13.2%)        
  4                                                                  7 (5.8%)         6 (5.0%)          
  5                                                                  9 (7.4%)         9 (7.4%)          
  Anatomic region^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                        0.132
  Truck                                                              16 (10.9%)       5 (3.4%)          
  Head/neck                                                          10 (6.8%)        4 (2.7%)          
  Extremities                                                        51 (34.7%)       47 (32.0%)        
  Mucosal                                                            7 (4.8%)         7 (4.8%)          
  Ulceration^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                             0.001^[a](#tfn18-ol-0-0-11219){ref-type="table-fn"}^
  With                                                               68 (51.9%)       26 (19.9%)        
  Without                                                            10 (7.6%)        27 (20.6%)        
  Metastasis^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                             0.002^[b](#tfn19-ol-0-0-11219){ref-type="table-fn"}^
  With                                                               53 (40.2%)       23 (17.4%)        
  Without                                                            24 (18.2%)       24 (18.2%)        
  T stage^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                                0.706
  pT0                                                                4 (3.0%)         0                 
  pT1                                                                21 (15.9%)       16 (12.1%)        
  pT2                                                                22 (16.6%)       23 (17.4%)        
  pT3                                                                19 (14.4%)       11 (8.3%)         
  pT4                                                                11 (8.3%)        5 (11.0%)         
  Histological type^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                      0.294
  ALM                                                                26 (22.2%)       16 (13.7%)        
  NM                                                                 1 (0.8%)         6 (5.1%)          
  SSM                                                                15 (12.8%)       14 (12.0%)        
  LMM                                                                6 (5.1%)         13 (11.1%)        
  MCM                                                                11 (9.4%)        6 (5.1%)          
  Unclassifiable                                                     3 (2.7%)         0                 
  Growth phase^[d](#tfn21-ol-0-0-11219){ref-type="table-fn"}^                                           0.065
  Radial                                                             22 (19.8%)       26 (23.4%)        
  Vertical                                                           40 (36.0%)       23 (20.7%)        

P\<0.001

P\<0.01

P-value based on t-test.

P-value based on χ^2^ test. SD, standard deviation; ADPS, serum albumin/D-dimer prognosis score; OS, overall survival; DFS, disease free survival; TNM, tumor node metastasis; T, tumor; ALM, acral lentiginous melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma; LMM, lentigo malignant melanoma; MCM, mucosal melanoma.
